Lung cancer

BRIDGE (D9106C00002)

A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Open at Paris since : 14/06/2024
Target : Adult
Phase : Phase II

Trial description

To assess the efficacy of neoadjuvant durvalumab +;CT in terms of resection rate in participants with;resectable and borderline resectable stage IIB-IIIB;NSCLC.;Resection rate defined as the proportion of all;participants who underwent definitive surgery.;The analysis will be performed in all participants who;received at least one dose of study intervention (FAS).

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact